Grade My Investments
HomeFree Stock Grades › OCGN

Ocugen, Inc. (OCGN) Stock Grade

OCGN · Healthcare

C
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$405.2M
P/E Ratio
Revenue Growth (YoY)
+8.8%
Net Margin
-1537.4%
Return on Equity
557.7%
Dividend Yield
None

About Ocugen, Inc.'s fundamentals

Ocugen is a biotechnology company with a market capitalization of $405.2 million that generated revenue growth of 8.8% year-over-year, indicating expanding commercial activity. However, the company reported a substantial net loss in its latest annual period, resulting in a negative net margin of -1537.4%, meaning it is currently unprofitable and burning cash relative to revenues. The company does not pay a dividend, which is typical for development-stage biotech firms, and the unusually high return on equity figure reflects the distortive effects of negative earnings on this metric.

Track OCGN free — no credit card required. Live grade + monthly AI report →